<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01215916</url>
  </required_header>
  <id_info>
    <org_study_id>11158</org_study_id>
    <secondary_id>H8K-MC-JZAE</secondary_id>
    <nct_id>NCT01215916</nct_id>
  </id_info>
  <brief_title>A Phase 1 Study in Patients With Solid Tumors</brief_title>
  <official_title>A Phase 1b Study of LY573636-sodium in Combination With Alimta (Pemetrexed) in Patients With Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to determine the MTD regimen for the combination
      therapy of LY573636 and pemetrexed that may be safely administered to patients with a solid
      tumor that is not amenable to curative therapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recommended phase 2 dose</measure>
    <time_frame>Baseline to study completion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with clinically significant effects</measure>
    <time_frame>Baseline to study completion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with a tumor response</measure>
    <time_frame>Baseline to study completion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics, concentration maximum (Cmax)</measure>
    <time_frame>Cycle 1, Cycle 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics, Area under the curve (AUC)</measure>
    <time_frame>Cycle 1, Cycle 2</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Pemetrexed followed by LY573636</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pemetrexed on Day 1 followed by LY573636 on Day 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY573636 followed by Pemetrexed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY573636 on Day 1, Pemetrexed on Day 4</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY573636</intervention_name>
    <description>Individualized dose is dependent on patients height, weight, gender and is adjusted to target a specific exposure range corrected for a patient's laboratory parameters. Intravenous dosing is completed once in a 28 day cycle.
Patients may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criterion are met.</description>
    <arm_group_label>Pemetrexed followed by LY573636</arm_group_label>
    <arm_group_label>LY573636 followed by Pemetrexed</arm_group_label>
    <other_name>Tasisulam</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <description>375-500 mg/m2, intravenous dosing is completed once each 28 day cycle.
Patients may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criterion are met.</description>
    <arm_group_label>Pemetrexed followed by LY573636</arm_group_label>
    <arm_group_label>LY573636 followed by Pemetrexed</arm_group_label>
    <other_name>LY231514</other_name>
    <other_name>Alimta</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  You must have a diagnosis of a solid tumor malignancy that is not amenable to curative
             therapy

          -  You must have a serum albumin level greater than or equal to 3.0 g/dL (30 g/L)

          -  You must have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group
             (ECOG) scale

          -  You must be reliable and willing to make yourself available for the duration of the
             study and are willing to follow study procedures

          -  Patients with reproductive potential should use medically approved contraceptive
             precautions during the trial and for 6 months following the last dose of study drugs

          -  Your test results assessing the function of your blood, kidneys, liver, and heart are
             satisfactory

          -  You must be willing to take folic acid, vitamin B12 or prophylactic steroids

          -  You must able to interrupt the use of aspirin (other than an aspirin dose less than or
             equal to 1.3 grams per day) and/or other nonsteroidal anti-inflammatory agents for 2
             days before, the day of, and 2 days after the dose of pemetrexed (5 days prior for
             long-acting agents, such as piroxicam).

          -  You must have discontinued all previous therapies for cancer, including chemotherapy,
             radiotherapy, immunotherapy, hormone therapy, or other investigational therapy for at
             least 4 weeks (6 weeks for mitomycin-C or nitrosoureas) before study enrollment and
             recovered from the acute effects of therapy (except alopecia). Patients who have
             received whole-brain radiation must wait 90 days before starting study therapy.

          -  You must sign an informed consent

        Exclusion Criteria:

          -  You cannot have received other investigational drugs within the last 30 days

          -  You cannot have other on-going serious illnesses including active bacterial, fugal, or
             viral infections

          -  You cannot require regular, periodic paracentesis or thoracentesis

          -  You cannot have active brain metastasis

          -  You cannot currently be receiving warfarin (CoumadinÂ®) therapy

          -  You cannot be pregnant or lactating

          -  You cannot have received prior Pemetrexed or LY573636

          -  You cannot have a second primary malignancy that could affect interpretation of the
             study results
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon.-Fri. 9 AM - 5 PM Eastern Time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 5, 2010</study_first_submitted>
  <study_first_submitted_qc>October 5, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2010</study_first_posted>
  <last_update_submitted>February 10, 2012</last_update_submitted>
  <last_update_submitted_qc>February 10, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 13, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Solid tumors</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>March 17, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

